STERIS plc STE
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE
Umsatz
$5.14B
+13.3% Jahresübergangsrate
Nettoerlös
$378.20M
+253.4% Jahresübergangsrate
Gesamtvermögen
$10.15B
-8.3% Jahresübergangsrate
EPS
3.81
+256.1% Jahresübergangsrate
Advertisement
Einkommensrechnung
| Zeitraum | 2027 Q1 | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Revenues | $1.39B | $5.14B | $3.98B | $2.61B | $1.28B | $4.54B | $3.72B | $2.42B |
| Cost of Revenue | $763.10M | — | $2.22B | $1.46B | $707.10M | — | $2.08B | $1.35B |
| Gross Profit | $628.00M | $2.22B | $1.76B | $1.15B | $572.40M | $1.98B | $1.64B | $1.08B |
| R&D Expense | $26.40M | $103.70M | $80.00M | $52.60M | $25.60M | $98.48M | $76.22M | $50.96M |
| SG&A Expense | $353.80M | $1.25B | $1.00B | $664.90M | $335.60M | $1.09B | $943.25M | $634.96M |
| Operating Income (Loss) | $246.00M | $836.10M | $650.50M | $405.20M | $185.50M | $791.10M | $615.78M | $389.31M |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | $177.40M | $378.20M | $469.00M | $295.40M | $145.40M | $107.03M | $379.62M | $238.87M |
| EPS (Diluted) | — | 3.81 | 4.73 | 2.98 | 1.46 | 1.07 | 3.82 | 2.41 |
Bilanz
| Zeitraum | 2027 Q1 | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.74B | $10.15B | $10.15B | $10.15B | $10.15B | $11.06B | $11.06B | $11.06B |
| Current Assets | $2.39B | $2.00B | $2.00B | $2.00B | $2.00B | $2.87B | $2.87B | $2.87B |
| Cash & Equivalents | $439.60M | — | $171.70M | $171.70M | $171.70M | — | $207.02M | $207.02M |
| Accounts Receivable | $1.09B | $1.04B | $1.04B | $1.04B | $1.04B | $1.01B | $1.01B | $1.01B |
| Inventory | $631.80M | $581.30M | $581.30M | $581.30M | $581.30M | $674.53M | $674.53M | $674.53M |
| PP&E (Net) | $2.16B | $1.96B | $1.96B | $1.96B | $1.96B | $1.77B | $1.77B | $1.77B |
| Goodwill | $4.19B | $4.07B | $4.10B | $4.10B | $4.10B | $3.88B | $4.07B | $4.07B |
| Total Liabilities | $3.54B | $3.53B | $3.53B | $3.53B | $3.53B | $4.75B | $4.75B | $4.75B |
| Current Liabilities | $1.15B | $1.02B | $1.02B | $1.02B | $1.02B | $931.13M | $931.13M | $931.13M |
| Accounts Payable | $338.80M | $280.80M | $280.80M | $280.80M | $280.80M | $251.72M | $251.72M | $251.72M |
| Long-Term Debt | $1.81B | $1.92B | $1.92B | $1.92B | $1.92B | $3.12B | $3.12B | $3.12B |
| Stockholders Equity | $7.18B | $6.60B | $6.60B | $6.60B | $6.60B | $6.30B | $6.30B | $6.30B |
Kassenfluss
| Zeitraum | 2027 Q1 | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $420.00M | $973.30M | $887.30M | $554.50M | $303.70M | $756.95M | $718.47M | $427.22M |
| Investing Cash Flow | $-108.50M | $-887.40M | $458.60M | $582.50M | $687.80M | $-383.33M | $-791.75M | $-672.83M |
| Financing Cash Flow | $-213.10M | $-85.20M | $-1.39B | $-1.18B | $-998.90M | $-498.72M | $58.58M | $256.58M |
| Stock Repurchases | $10.60M | $11.80M | $211.10M | $110.60M | $64.20M | $308.56M | $11.44M | $9.21M |
Ähnliche Firmen
ALIGN TECHNOLOGY INC
ALGN
Edwards Lifesciences Corp
EW
INTUITIVE SURGICAL INC
ISRG
ZIMMER BIOMET HOLDINGS, INC.
ZBH
Mehr erfahren
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Daten stammen aus der öffentlichen Datenbank des US-amerikanischen SEC EDGAR. Diese Seite bietet keine Anlageberatung.